SEC
FATE icon

Seven Eight Capital’s Fate Therapeutics FATE Stock Holding History

Seven Eight Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-213,733
Closed -$2.16M – 484
2022
Q4 		$2.16M Buy
213,733
+193,119
+937% +$3.63M 0.56% 45
2022
Q3 		$462K Buy
+20,614
New +$596K 0.09% 293
2021
Q2 		– Sell
-15,503
Closed -$1.41M – 622
2021
Q1 		$1.41M Hold
15,503
– – 0.32% 118
2020
Q4 		$1.41M Buy
15,503
+9,900
+177% +$615K 0.32% 119
2020
Q3 		$224K Buy
+5,603
New +$196K 0.05% 503

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Seven Eight Capital's FATE Position: Q1 2023 in Review

Seven Eight Capital sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 213,733 shares — an estimated $2.16M sold.

Seven Eight Capital first reported a position in FATE in Q3 2020 and held it in 5 quarters. The position peaked at $2.16M in Q4 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Seven Eight Capital reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Seven Eight Capital sold 213,733 Fate Therapeutics shares in Q1 2023, an estimated $2.16M.
  • Seven Eight Capital first reported a position in Fate Therapeutics in Q3 2020 and held it in 5 quarters.
  • Seven Eight Capital's Fate Therapeutics position peaked at $2.16M in Q4 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Seven Eight Capital's 13F filing for Q1 2023, filed 15 May 2023.